{"filing":{"accession_number":"0001213900-26-087224","cik":"0001871321","ticker":"DRTSW","company_name":"Alpha Tau Medical Ltd.","form":"6-K","filing_date":"2026-08-10","report_date":"2026-06-30","primary_document":"ea0300791-6k_alpha.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1871321/000121390026087224/ea0300791-6k_alpha.htm"},"events":[{"id":26509,"run_id":24095,"accession_number":"0001213900-26-087224","anchor_item_number":"EX-99.3","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"This is a press release dated August 10, 2026, announcing Alpha Tau's second quarter 2026 financial results, including R\u0026D expenses of $20.9M, net loss of $68.8M ($0.76 per share), and cash balance of $104.8M. The release also discloses significant clinical and corporate milestones (REGAIN glioblastoma trial results, ReSTART enrollment completion, Tolmar partnership with $20M equity investment and $161.5M in milestone payments). While the exhibit bundles multiple announcements, the primary disclosure is the quarterly financial results with accompanying operational updates, making this an earnings release.","company_name":"Alpha Tau Medical Ltd.","ticker":"DRTSW","filing_date":"2026-08-10","form":"6-K","submitted_at":null,"items":[{"id":27661,"accession_number":"0001213900-26-087224","item_number":"EX-99.3","item_title":"ea030079101ex99-3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release dated August 10, 2026, announcing Alpha Tau's second quarter 2026 financial results, including R\u0026D expenses of $20.9M, net loss of $68.8M ($0.76 per share), and cash balance of $104.8M. The release also discloses significant clinical and corporate milestones (REGAIN glioblastoma trial results, ReSTART enrollment completion, Tolmar partnership with $20M equity investment and $161.5M in milestone payments). While the exhibit bundles multiple announcements, the primary disclosure is the quarterly financial results with accompanying operational updates, making this an earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:04:55.748763+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27659,"accession_number":"0001213900-26-087224","item_number":"EX-99.1","item_title":"ea030079101ex99-1.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is an unaudited interim consolidated financial statement for the six-month period ended June 30, 2026, comprising balance sheets, statements of operations, changes in shareholders' equity, cash flows, and accompanying notes. It is a periodic financial report, not a discrete event or earnings release announcement. The document is explicitly labeled \"UNAUDITED\" and represents the company's interim financial position and results for the first half of 2026, which is the foreign-issuer equivalent of a 10-Q quarterly report.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:04:55.748763+00:00","company_name":"Alpha Tau Medical Ltd.","ticker":"DRTSW","filing_date":"2026-08-10"},{"id":27660,"accession_number":"0001213900-26-087224","item_number":"EX-99.2","item_title":"ea030079101ex99-2.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is an \"Operating and Financial Review and Prospects\" document explicitly tied to \"unaudited consolidated financial statements as of and for the six months ended June 30, 2025 and 2026.\" It is a periodic interim financial report (the foreign-issuer equivalent of a 10-Q), not a discrete event or earnings release. The document itself is the periodic report, which should be deferred for separate processing rather than classified as an event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:04:55.748763+00:00","company_name":"Alpha Tau Medical Ltd.","ticker":"DRTSW","filing_date":"2026-08-10"},{"id":27661,"accession_number":"0001213900-26-087224","item_number":"EX-99.3","item_title":"ea030079101ex99-3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release dated August 10, 2026, announcing Alpha Tau's second quarter 2026 financial results, including R\u0026D expenses of $20.9M, net loss of $68.8M ($0.76 per share), and cash balance of $104.8M. The release also discloses significant clinical and corporate milestones (REGAIN glioblastoma trial results, ReSTART enrollment completion, Tolmar partnership with $20M equity investment and $161.5M in milestone payments). While the exhibit bundles multiple announcements, the primary disclosure is the quarterly financial results with accompanying operational updates, making this an earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:04:55.748763+00:00","company_name":"Alpha Tau Medical Ltd.","ticker":"DRTSW","filing_date":"2026-08-10"}]}